Literature DB >> 20348930

Diabetic nephropathy: Aldosterone breakthrough in patients on an ACEI.

Takahiko Nakagawa.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20348930     DOI： 10.1038/nrneph.2010.32

Source DB:  PubMed          Journal:  Nat Rev Nephrol        ISSN： 1759-5061            Impact factor:   28.314


× No keyword cloud information.
  10 in total

1.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Authors:  B M Brenner; M E Cooper; D de Zeeuw; W F Keane; W E Mitch; H H Parving; G Remuzzi; S M Snapinn; Z Zhang; S Shahinfar
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  Endothelial cell nitric oxide inhibits aldosterone synthesis in zona glomerulosa cells: modulation by oxygen.

Authors:  C J Hanke; W B Campbell
Journal:  Am J Physiol Endocrinol Metab       Date:  2000-10       Impact factor: 4.310

3.  Spironolactone suppresses inflammation and prevents L-NAME-induced renal injury in rats.

Authors:  Hirofumi Ikeda; Kazuhiko Tsuruya; Jiro Toyonaga; Kohsuke Masutani; Hideko Hayashida; Hideki Hirakata; Mitsuo Iida
Journal:  Kidney Int       Date:  2008-10-15       Impact factor: 10.612

4.  Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy.

Authors:  Uzma F Mehdi; Beverley Adams-Huet; Philip Raskin; Gloria L Vega; Robert D Toto
Journal:  J Am Soc Nephrol       Date:  2009-11-19       Impact factor: 10.121

5.  Renal and retinal effects of enalapril and losartan in type 1 diabetes.

Authors:  Michael Mauer; Bernard Zinman; Robert Gardiner; Samy Suissa; Alan Sinaiko; Trudy Strand; Keith Drummond; Sandra Donnelly; Paul Goodyer; Marie Claire Gubler; Ronald Klein
Journal:  N Engl J Med       Date:  2009-07-02       Impact factor: 91.245

6.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

Authors:  Johannes F E Mann; Roland E Schmieder; Matthew McQueen; Leanne Dyal; Helmut Schumacher; Janice Pogue; Xingyu Wang; Aldo Maggioni; Andrzej Budaj; Suphachai Chaithiraphan; Kenneth Dickstein; Matyas Keltai; Kaj Metsärinne; Ali Oto; Alexander Parkhomenko; Leopoldo S Piegas; Tage L Svendsen; Koon K Teo; Salim Yusuf
Journal:  Lancet       Date:  2008-08-16       Impact factor: 79.321

7.  In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria.

Authors:  Bruce A Perkins; Linda H Ficociello; Bijan Roshan; James H Warram; Andrzej S Krolewski
Journal:  Kidney Int       Date:  2010-01       Impact factor: 10.612

8.  ACE-inhibitor use and the long-term risk of renal failure in diabetes.

Authors:  S Suissa; T Hutchinson; J M Brophy; A Kezouh
Journal:  Kidney Int       Date:  2006-03       Impact factor: 10.612

9.  eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists.

Authors:  Tomoki Kosugi; Marcelo Heinig; Takahiro Nakayama; Seiichi Matsuo; Takahiko Nakagawa
Journal:  Am J Pathol       Date:  2009-12-30       Impact factor: 4.307

10.  Endothelium-derived nitric oxide modulates vascular action of aldosterone in renal arteriole.

Authors:  Shuji Arima; Kentaro Kohagura; Hong-Lan Xu; Akira Sugawara; Akira Uruno; Fumitoshi Satoh; Kazuhisa Takeuchi; Sadayoshi Ito
Journal:  Hypertension       Date:  2003-12-22       Impact factor: 10.190
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.